- Bayer to make 'careful but aggressive' return to pharma M&A, CEO saysBayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill Anderson. “We’re going to be careful, but also aggressive,” Anderson said on a first-qu…Endpoints · 2mo ago↗ source
- Alkermes' narcolepsy Phase 3 success; Boehringer's antibody dealPlus, news from Vistagen, Enterprise Therapeutics, Cerevance and Memento Medicines. 😴 Alkermes’ narcolepsy drug succeeds in Phase 3 study: The company’s drug Lumryz, approved in 2023 for narcoleps…Endpoints · 2mo ago↗ source
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.